Ropinirole drug data and news

---

Long-Term Ropinirole for Restless Legs Syndrome Tolerable ...  May 5, 2006
CHICAGO, IL -- May 5, 2006 -- Long-term use of the dopamine agonist ropinirole appears to be generally well tolerated in patients with restless legs syndrome ... - DG News

Disease mongering Restless Legs Syndrome: A case study of how the ...  May 11, 2006
...beginning with press releases about presentations at the American Academy of Neurology meeting describing the early trial results of using ropinirole (a drug ... - Newstarget.com,

Parkinson Disease Guidelines Aid Diagnosis, Management  May 9, 2006
Also recommended, but backed by less robust evidence, are the dopamine agonists ropinirole, pramipexole, and pergolide, and another catechol-O ... - Journal of American Medical Association (subscription),

Financial: Glaxo denies pushing 'lifestyle' treatments: 'Restless ...  Apr 28, 2006
...authors of the report highlighted the "restless legs" syndrome, described by GSK as "common yet unrecognised" when it launched its Ropinirole treatment last ... - Therapeutics Daily (subscription) (press release),

Restless Legs Syndrome In Adults: Comparing Immediate Release ...  Apr 19, 2006
...the safety profile and to evaluate the clinical benefits (as assessed by efficacy endpoints and patient-reported outcomes) of ropinirole extended release ... - Community Dispatch (press release)

PLoS Medicine challenges "disease mongering"  May 5, 2006
GSK has been accused of creating the "restless legs" syndrome as part of its marketing activities around the launch of its Ropinirole drug. ... - Information World Review,

SkyePharma PLC - Preliminary Results Announcement for the Year ...  Apr 19, 2006
December 2005, SkyePharma's collaborator GlaxoSmithKline submitted Requip Once-a-day, a once-daily dosage formulation of Requip(R) (ropinirole), for approval ... - PR Newswire (press release),

Healthcare: At a Glance - Pharma Firms Slammed for 'Disease ...  Apr 21, 2006
...depression. Indeed - GSK is behind a treatment called Requip (ropinirole), which it hopes to market as Adartrel in the UK. Clew ... - International News Service,

P ₄₅₀ Interaction:    In vitro metabolism studies showed that CYP1A2 was the major enzyme responsible for the metabolism of ropinirole. There is thus the potential for substrates or inhibitors of this enzyme when coadministered with ropinirole to alter its clearance. Therefore, if therapy with a drug known to be a potent inhibitor of CYP1A2 is stopped or started during treatment with Requip , adjustment of the Requip dose may be required.

L-dopa:   Co-administration of carbidopa + L-dopa (Sinemet® 10/100 mg b.i.d.) with ropinirole (2.0 mg t.i.d.) had no effect on the steady-state pharmacokinetics of ropinirole (n=28 patients). Oral administration of Requip 2.0 mg t.i.d. increased mean steady state C _max of L-dopa by 20% but its AUC was unaffected (n=23 patients).

Digoxin:   Co-administration of Requip (2.0 mg t.i.d.) with digoxin (0.125-0.25 mg q.d.) did not alter the steady-state pharmacokinetics of digoxin in 10 patients.

Theophylline:    Administration of theophylline (300 mg b.i.d., a substrate of CYP1A2) did not alter the steady-state pharmacokinetics of ropinirole (2 mg t.i.d.) in 12 patients with Parkinson's disease. Ropinirole (2 mg t.i.d.) did not alter the pharmacokinetics of theophylline (5 mg/kg i.v.) in 12 patients with Parkinson's disease.

Ciprofloxacin:   Co-administration of ciprofloxacin (500 mg b.i.d.), an inhibitor of CYP1A2, with ropinirole (2 mg t.i.d.) increased ropinirole AUC by 84% on average, and C _max by 60% (n=12 patients).

Estrogens:   Population pharmacokinetic analysis revealed that estrogens (mainly ethinylestradiol: intake 0.6-3 mg over 4-month to 23-year period) reduced the oral clearance of ropinirole by 36% in 16 patients. Dosage adjustment may not be needed for Requip in patients on estrogen therapy because patients must be carefully titrated with ropinirole to tolerance or adequate effect. However, if estrogen therapy is stopped or started during treatment with Requip , then adjustment of the Requip (ropinirole hydrochloride) dose may be required.

Dopamine Antagonists:   Since ropinirole is a dopamine agonist, it is possible that dopamine antagonists, such as neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of Requip . Patients with major psychotic disorders, treated with neuroleptics, should only be treated with dopamine agonists if the potential benefits outweigh the risks.

Population analysis showed that commonly administered drugs, e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, and anticholinergics did not affect the oral clearance of ropinirole.